Currently out of the existing stock ratings of Kristen Kluska, 283 are a BUY (91.59%), 26 are a HOLD (8.41%).

Kristen Kluska

Work Performance Price Targets & Ratings Chart

Analyst Kristen Kluska, currently employed at CANTOR FITZGERALD, carries an average stock price target met ratio of 36.19% that have a potential upside of 35.88% achieved within 118 days.

Kristen Kluska’s has documented 580 price targets and ratings displayed on 52 stocks. The coverage is on Healthcare, Industrials sectors.

Most recent stock forecast was given on RARE, Ultragenyx at 19-Aug-2026.

Wall Street Analyst Kristen Kluska

Analyst best performing recommendations are on QURE (UNIQURE NV).
The best stock recommendation documented was for QURE (UNIQURE NV) at 9/22/2025. The price target of $47 was fulfilled within 2 days with a profit of $33.17 (239.84%) receiving and performance score of 1199.2.

Average potential price target upside

of $34.89 (91.15%) on IRON (DISC MEDICINE).
of $30.04 (85.02%) on PTE (POLARITYTE).
of $28.2 (49.85%) on GLMD (GALMED PHARMACEUTICALS LTD).

CLDX Celldex Therapeutics HTBX Heat Biologics MBIO Mustang Bio OCGN Ocugen PTE Polarityte RIGL Rigel Pharmaceuticals OCUP Ocuphire Pharma ADMA ADMA Biologics BTX Brooklyn Immunotherapeutics ETNB 89bio FOLD Amicus Therapeutics ABEO Abeona Therapeutics ETN Eaton PLC SRPT Sarepta Therapeutics AGTC Applied Genetic DRRX Durect EVLO Evelo Biosciences MREO Mereo BioPharma Group PLC ADR OTLK OUTLOOK THERAPEUTICS INC SELB Selecta Biosciences TSHA Taysha Gene Therapies XFOR X4 Pharmaceuticals CBAY Cymabay Therapeu GLMD Galmed Pharmaceuticals Ltd HUMA Humacyte IBIO Ibio PTCT PTC Therapeutics SLNO Soleno Therapeutics RARE Ultragenyx CAPR Capricor Therapeutics CDXS Codexis FULC Fulcrum Therapeutics QURE Uniqure NV IRON Disc Medicine SKYE Skye Bioscience, Common Stock PTI Proteostasis Therapeutics SUPN Supernus Pharmaceuticals PHGE Biomx AQST Aquestive Therapeutics ESPR Esperion Therapeutics PHAT Phathom Pharmaceuticals ATNM Actinium Pharmaceuticals AXGT Sio Gene Therapies CMMB Chemomab Therapeutics Ltd DRC DBVT DBV Technologies GL Globe Life LCTX Lineage Cell Therapeutics LXEO Lexeo Therapeutics, Common Stock MRKR Marker Therapeutics OC Owens Corning PHG Koninklijke Philips NV ADR RNAC Cartesian Therapeutics

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Judah Frommer (MORGAN STANLEY)